NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its fourth quarter and full year ended December 31, 2017.
The Company’s worldwide revenues for the fourth quarter of 2017 totaled $81.2 million. This represents an increase of 9.3% compared to $74.4 million for the fourth quarter of 2016. For the full year 2017, worldwide revenues totaled $331.4 million, compared to $301.9 million in 2016. Excluding the impact of a $5.0 million up-front payment received in the second quarter of 2017 from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement, full year 2017 revenue totaled $326.4 million, exceeding 2017 guidance of $323 million to $325 million. Full year revenue results were driven by 19.5% growth in worldwide sales of DEFINITY®, 5.5% growth in worldwide sales of TechneLite® and 7.9% growth in worldwide sales of Xenon.
Net income for the fourth quarter of 2017 totaled $97.1 million, or $2.47 per diluted share, compared to $4.9 million, or $0.13 per diluted share, for the fourth quarter of 2016. Full year 2017 net income totaled $123.4 million, compared to $26.8 million in 2016. The full year improvement is primarily attributable to the release of our valuation allowance against deferred tax assets, as well as DEFINITY and Xenon revenue growth and lower interest expense following the refinancing and subsequent repricing of our debt facility during 2017. This was partially offset by increased operating expenses for sales and marketing as well as costs related to strategic initiatives.
The Company’s fourth quarter 2017 Adjusted EBITDA (as outlined in the GAAP to non-GAAP reconciliation provided below) was $20.8 million, or 25.7% of revenues, compared to $19.8 million, or 26.7% of revenues, for the fourth quarter of 2016. Full year 2017 Adjusted EBITDA was $94.1 million, or 28.4% of revenues, compared to $78.3 million, or 25.9% of revenues, for 2016. Excluding the impact of a $5.0 million up-front payment received in the second quarter of 2017 from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement, full year Adjusted EBITDA totaled $89.1 million, or 27.3% of revenues, exceeding 2017 guidance of $86 million to $88 million. Higher Adjusted EBITDA for full year 2017 was driven by DEFINITY and Xenon revenue growth, partially offset by sales and marketing expenses attributable to sales growth in DEFINITY as well as costs related to strategic initiatives.
“We are pleased to announce such a successful finish to 2017, a milestone year for the Company on many fronts,” commented Mary Anne Heino, President and CEO. “Our performance and improved balance sheet have positioned us well to make the requisite investments in our own internal initiatives as well as potential external opportunities to augment our strong core business and future growth.”
Outlook
The Company anticipates worldwide revenues for full year 2018 of approximately $337 million to $342 million, compared to $326.4 million in 2017 (which excludes the $5 million up-front payment received from GE Healthcare). For the first quarter of 2018, the Company expects worldwide revenues in the range of $78 million to $83 million.
The Company anticipates full year 2018 Adjusted EBITDA, as described in the GAAP to non-GAAP reconciliation provided later in this release, of $85 million to $90 million, representing 24.9% to 26.7% of anticipated worldwide revenues. For the first quarter of 2018, the Company expects Adjusted EBITDA in the range of $18 million to $21 million.
The Company’s guidance for worldwide revenues and Adjusted EBITDA are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from guidance. Forward-looking statements are not predictions of the Company’s actual performance. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.
Internet Posting of Information
The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.
Conference Call and Webcast
As previously announced, the Company will host a conference call starting at 4:30 p.m. Eastern Time today. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 9165309. A live audio webcast of the call also will be available in the Investors section of the Company’s website at www.lantheus.com.
A replay of the audio webcast will be available in the Investors section of our website at www.lantheus.com approximately two hours after completion of the call and will be archived for 30 days.
The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.
The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as revenues excluding the impact of foreign currency; adjusted operating income; adjusted net income and its line components; Adjusted EBITDA; adjusted net income per share - diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. The measures may exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company’s reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including statements about our 2018 outlook. Forward-looking statements may be identified by their use of terms such as anticipate, believe, confident, could, estimate, expect, intend, may, plan, predict, project, target, will and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward- looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). This press release includes forward-looking non-GAAP guidance for 2018 Adjusted EBITDA. No reconciliation of this forward-looking non-GAAP guidance was included in this press release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information and the fact that some of the excluded information is not readily ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.
– Tables Follow –
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
(in thousands, except per share data – unaudited) |
||||||||||||||||
|
|
Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenues | $ | 81,241 | $ | 74,350 | $ | 331,378 | $ | 301,853 | ||||||||
| Cost of goods sold | 43,342 | 39,703 | 169,243 | 164,073 | ||||||||||||
| Gross profit | 37,899 | 34,647 | 162,135 | 137,780 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 10,423 | 8,686 | 42,315 | 36,542 | ||||||||||||
| General and administrative | 14,293 | 9,990 | 49,842 | 38,832 | ||||||||||||
| Research and development | 3,976 | 3,710 | 18,125 | 12,203 | ||||||||||||
| Total operating expenses | 28,692 | 22,386 | 110,282 | 87,577 | ||||||||||||
| Gain (loss) on sales of assets | — | (120 | ) | — | 6,385 | |||||||||||
| Operating income | 9,207 | 12,141 | 51,853 | 56,588 | ||||||||||||
| Interest expense | 4,263 | 5,819 | 18,410 | 26,618 | ||||||||||||
| Debt retirement costs | — | 481 | — | 1,896 | ||||||||||||
| Loss on extinguishment of debt | 281 | — | 2,442 | — | ||||||||||||
| Other (income) expense | (6,601 | ) | 97 | (8,638 | ) | (220 | ) | |||||||||
| Income before income taxes | 11,264 | 5,744 | 39,639 | 28,294 | ||||||||||||
| Income tax (benefit) provision | (85,862 | ) | 875 | (83,746 | ) | 1,532 | ||||||||||
| Net income | $ | 97,126 | $ | 4,869 | $ | 123,385 | $ | 26,762 | ||||||||
| Net income per common share: | ||||||||||||||||
| Basic | $ | 2.58 | $ | 0.13 | $ | 3.31 | $ | 0.84 | ||||||||
| Diluted | $ | 2.47 | $ | 0.13 | $ | 3.17 | $ | 0.82 | ||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic | 37,580 | 36,173 | 37,276 | 32,044 | ||||||||||||
| Diluted | 39,294 | 37,853 | 38,892 | 32,656 | ||||||||||||
|
Lantheus Holdings, Inc. |
||||||||||||||||||||||
|
Consolidated Segment Revenues Analysis |
||||||||||||||||||||||
|
(in thousands – unaudited) |
||||||||||||||||||||||
|
Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||||||||
| 2017 | 2016 | % Change | 2017 | 2016 | % Change | |||||||||||||||||
|
United States |
||||||||||||||||||||||
| DEFINITY | $ | 40,546 | $ | 33,180 | 22.2 | % | $ | 153,581 | $ | 128,677 | 19.4 | % | ||||||||||
| TechneLite | 21,339 | 21,130 | 1.0 | % | 90,489 | 85,412 | 5.9 | % | ||||||||||||||
| Xenon | 7,664 | 7,458 | 2.8 | % | 31,373 | 29,078 | 7.9 | % | ||||||||||||||
| Other | 1,747 | 2,965 | (41.1 | )% | 14,559 | 14,253 | 2.1 | % | ||||||||||||||
| Total United States | 71,296 | 64,733 | 10.1 | % | 290,002 | 257,420 | 12.7 | % | ||||||||||||||
|
International |
||||||||||||||||||||||
| DEFINITY | 1,153 | 932 | 23.7 | % | 3,687 | 2,935 | 25.6 | % | ||||||||||||||
| TechneLite | 3,405 | 3,466 | (1.8 | )% | 14,155 | 13,805 | 2.5 | % | ||||||||||||||
| Xenon | — | 2 | (100.0 | )% | 4 | 8 | (50.0 | )% | ||||||||||||||
| Other | 5,387 | 5,217 | 3.3 | % | 23,530 | 27,685 | (15.0 | )% | ||||||||||||||
| Total International | 9,945 | 9,617 | 3.4 | % | 41,376 | 44,433 | (6.9 | )% | ||||||||||||||
|
Worldwide |
||||||||||||||||||||||
| DEFINITY | 41,699 | 34,112 | 22.2 | % | 157,268 | 131,612 | 19.5 | % | ||||||||||||||
| TechneLite | 24,744 | 24,596 | 0.6 | % | 104,644 | 99,217 | 5.5 | % | ||||||||||||||
| Xenon | 7,664 | 7,460 | 2.7 | % | 31,377 | 29,086 | 7.9 | % | ||||||||||||||
| Other | 7,134 | 8,182 | (12.8 | )% | 38,089 | 41,938 | (9.2 | )% | ||||||||||||||
| Total Revenues | $ | 81,241 | $ | 74,350 | 9.3 | % | $ | 331,378 | $ | 301,853 | 9.8 | % | ||||||||||
|
Lantheus Holdings, Inc. |
|||||||||||||||
|
Supplemental Revenue Information |
|||||||||||||||
|
(unaudited) |
|||||||||||||||
| December 31, 2017 | |||||||||||||||
| Quarter to Date Sales Growth/(Decline) | |||||||||||||||
|
Domestic |
Int’l |
Int’l As |
Total |
Total As |
|||||||||||
| Products | |||||||||||||||
| DEFINITY | 22.2 | % | 20.0 | % | 23.7 | % | 22.1 | % | 22.2 | % | |||||
| TechneLite | 1.0 | % | (5.7 | )% | (1.8 | )% | — | % | 0.6 | % | |||||
| Xenon | 2.8 | % | (100.0 | )% | (100.0 | )% | 2.7 | % | 2.7 | % | |||||
| Other | (41.1 | )% | 2.8 | % | 3.3 | % | (13.1 | )% | (12.8 | )% | |||||
| Total Revenues | 10.1 | % | 1.4 | % | 3.4 | % | 9.0 | % | 9.3 | % | |||||
| December 31, 2017 | |||||||||||||||
| Year to Date Sales Growth/(Decline) | |||||||||||||||
|
Domestic |
Int’l |
Int’l As |
Total |
Total As |
|||||||||||
| Products | |||||||||||||||
| DEFINITY | 19.4 | % | 23.7 | % | 25.6 | % | 19.5 | % | 19.5 | % | |||||
| TechneLite | 5.9 | % | 0.8 | % | 2.5 | % | 5.2 | % | 5.5 | % | |||||
| Xenon | 7.9 | % | (50.0 | )% | (50.0 | )% | 7.9 | % | 7.9 | % | |||||
| Other | 2.1 | % | (14.9 | )% | (15.0 | )% | (9.1 | )% | (9.2 | )% | |||||
| Total Revenues | 12.7 | % | (7.5 | )% | (6.9 | )% | 9.7 | % | 9.8 | % | |||||
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Reconciliation of Revenues to Revenues Excluding the Impact of Foreign Currency |
||||||||||||||||
|
(in thousands – unaudited) |
||||||||||||||||
|
Three Months Ended December 31, 2017 |
Year Ended December 31, 2017 |
|||||||||||||||
|
International |
Total |
International |
Total |
|||||||||||||
| Revenues | $ | 9,945 | $ | 81,241 | $ | 41,376 | $ | 331,378 | ||||||||
| Currency impact as compared to prior period | (194 | ) | (194 | ) | (274 | ) | (274 | ) | ||||||||
| Revenues, excluding the impact of foreign currency | $ | 9,751 | $ | 81,047 | $ | 41,102 | $ | 331,104 | ||||||||
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||||||||||
|
(in thousands – unaudited) |
||||||||||||||||
|
Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Operating income | $ | 9,207 | $ | 12,141 | $ | 51,853 | $ | 56,588 | ||||||||
| Campus consolidation costs including depreciation | 731 | 1,181 | 6,510 | 1,181 | ||||||||||||
| Offering and other costs | (26 | ) | 117 | 576 | 117 | |||||||||||
| Non-recurring refinancing related fees | 836 | — | 2,557 | — | ||||||||||||
| Loss (gain) on sales of assets | — | 120 | — | (6,385 | ) | |||||||||||
| One-time contract and termination costs | 2,210 | — | 2,210 | — | ||||||||||||
| Loss on impairment of land | 912 | — | 912 | — | ||||||||||||
| Adjusted operating income | $ | 13,870 | $ | 13,559 | $ | 64,618 | $ | 51,501 | ||||||||
| Adjusted operating income, as a percentage of revenues | 17.1 | % | 18.2 | % | 19.5 | % | 17.1 | % | ||||||||
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||||||||||
|
(in thousands, except per share data – unaudited) |
||||||||||||||||
|
Three Months Ended |
Year Ended |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Net income | $ | 97,126 | $ | 4,869 | $ | 123,385 | $ | 26,762 | ||||||||
| Reconciling items impacting operating income: | ||||||||||||||||
| Campus consolidation costs including depreciation | 731 | 1,181 | 6,510 | 1,181 | ||||||||||||
| Offering and other costs | (26 | ) | 117 | 576 | 117 | |||||||||||
| Non-recurring refinancing related fees | 836 | — | 2,557 | — | ||||||||||||
| Loss (gain) on sales of assets | — | 120 | — | (6,385 | ) | |||||||||||
| One-time contract and termination costs | 2,210 | — | 2,210 | — | ||||||||||||
| Reconciling items impacting non-operating expenses and income taxes: | ||||||||||||||||
| Loss on impairment of land | 912 | — | 912 | — | ||||||||||||
| Loss on debt extinguishment and retirement costs | 281 | 481 | 2,442 | 1,896 | ||||||||||||
| Income tax benefit for release of valuation allowance | (141,094 | ) | — | (141,094 | ) | — | ||||||||||
| Impact of tax rate change on deferred taxes | 45,129 | — | 45,129 | — | ||||||||||||
| Income tax effect of non-GAAP adjustments(a) | (1,248 | ) | — | (3,840 | ) | — | ||||||||||
| Adjusted net income | $ | 4,857 | $ | 6,768 | $ | 38,787 | $ | 23,571 | ||||||||
| Adjusted net income, as a percentage of revenues | 6.0 | % | 9.1 | % | 11.7 | % | 7.8 | % | ||||||||
|
Three Months Ended |
Year Ended |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Net income per share - diluted | $ | 2.47 | $ | 0.13 | $ | 3.17 | $ | 0.82 | ||||||||
| Reconciling items impacting operating income: | ||||||||||||||||
| Campus consolidation costs including depreciation | 0.02 | 0.04 | 0.17 | 0.04 | ||||||||||||
| Offering and other costs | — | — | 0.01 | — | ||||||||||||
| Non-recurring refinancing related fees | 0.02 | — | 0.07 | — | ||||||||||||
| Loss (gain) on sales of assets | — | — | — | (0.20 | ) | |||||||||||
| One-time contract and termination costs | 0.06 | — | 0.06 | — | ||||||||||||
| Reconciling items impacting non-operating expenses and income taxes: | ||||||||||||||||
| Loss on impairment of land | 0.02 | — | 0.02 | — | ||||||||||||
| Loss on debt extinguishment and retirement costs | 0.01 | 0.01 | 0.06 | 0.06 | ||||||||||||
| Income tax benefit for release of valuation allowance | (3.60 | ) | — | (3.62 | ) | — | ||||||||||
| Impact of tax rate change on deferred taxes | 1.15 | — | 1.16 | — | ||||||||||||
| Tax effect of non-GAAP adjustments(a) | (0.03 | ) | — | (0.10 | ) | — | ||||||||||
| Adjusted net income per share - diluted | $ | 0.12 | $ | 0.18 | $ | 1.00 | $ | 0.72 | ||||||||
| Weighted-average common shares outstanding - diluted | 39,294 | 37,853 | 38,892 | 32,656 | ||||||||||||
(a) The income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
|
Lantheus Holdings, Inc. |
|||||||||||||||||||||||
|
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information |
|||||||||||||||||||||||
|
Certain Line Items and Other Information |
|||||||||||||||||||||||
|
(in thousands, except per share data – unaudited) |
|||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| December 31, 2017 | December 31, 2016 | ||||||||||||||||||||||
| GAAP | Adjustments |
Non-GAAP |
GAAP | Adjustments |
Non-GAAP |
||||||||||||||||||
| Cost of goods sold | $ | 43,342 | $ | (1,200 | ) | (a) | $ | 42,142 | $ | 39,703 | $ | — | $ | 39,703 | |||||||||
| Gross profit | $ | 37,899 | $ | 1,200 | $ | 39,099 | $ | 34,647 | $ | — | $ | 34,647 | |||||||||||
| General and administrative | $ | 14,293 | $ | (3,463 | ) | (b) | $ | 10,830 | $ | 9,990 | $ | (117 | ) | (d) | $ | 9,873 | |||||||
| Research and development | $ | 3,976 | $ | — | $ | 3,976 | $ | 3,710 | $ | (1,181 | ) | (e) | $ | 2,529 | |||||||||
| Loss on sales of assets | $ | — | $ | — | $ | — | $ | (120 | ) | $ | 120 | $ | — | ||||||||||
| Operating income | $ | 9,207 | $ | 4,663 | $ | 13,870 | $ | 12,141 | $ | 1,418 | $ | 13,559 | |||||||||||
| Debt retirement costs | $ | — | $ | — | $ | — | $ | 481 | $ | (481 | ) | $ | — | ||||||||||
| Loss on extinguishment of debt | $ | 281 | $ | (281 | ) | $ | — | $ | — | $ | — | $ | — | ||||||||||
| Income before income taxes | $ | 11,264 | $ | 4,944 | $ | 16,208 | $ | 5,744 | $ | 1,899 | $ | 7,643 | |||||||||||
| Income tax (benefit) provision | $ | (85,862 | ) | $ | 97,213 | (c) | $ | 11,351 | $ | 875 | $ | — | $ | 875 | |||||||||
| Net income | $ | 97,126 | $ | (92,269 | ) | $ | 4,857 | $ | 4,869 | $ | 1,899 | $ | 6,768 | ||||||||||
| Net income per common share - diluted | $ | 2.47 | $ | 0.12 | $ | 0.13 | $ | 0.18 | |||||||||||||||
(a) One-time contract and termination costs.
(b) Includes campus consolidation costs (including depreciation expense) of $0.7 million, one-time contract and termination costs of $1.0 million, non-recurring refinancing related fees of $0.8 million, loss on impairment of land of $0.9 million and offering and other costs.
(c) Includes the income tax effect of non-GAAP adjustments and the income tax benefit due to the release of our valuation allowance of $141.1 million against our deferred tax assets offset by a provision of $45.1 million for the remeasurement of our deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.
(d) Offering and other costs.
(e) Campus consolidation costs (including depreciation expense).
|
Lantheus Holdings, Inc. |
|||||||||||||||||||||||
|
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information |
|||||||||||||||||||||||
|
Certain Line Items and Other Information |
|||||||||||||||||||||||
|
(in thousands, except per share data – unaudited) |
|||||||||||||||||||||||
| Twelve Months Ended | |||||||||||||||||||||||
| December 31, 2017 | December 31, 2016 | ||||||||||||||||||||||
| GAAP | Adjustments |
Non-GAAP |
GAAP | Adjustments |
Non-GAAP |
||||||||||||||||||
| Cost of goods sold | $ | 169,243 | $ | (1,200 | ) | (a) | $ | 168,043 | $ | 164,073 | $ | — | $ | 164,073 | |||||||||
| Gross profit | $ | 162,135 | $ | 1,200 | $ | 163,335 | $ | 137,780 | $ | — | $ | 137,780 | |||||||||||
| General and administrative | $ | 49,842 | $ | (11,565 | ) | (b) | $ | 38,277 | $ | 38,832 | $ | (117 | ) | (d) | $ | 38,715 | |||||||
| Research and development | $ | 18,125 | $ | — | $ | 18,125 | $ | 12,203 | $ | (1,181 | ) | (e) | $ | 11,022 | |||||||||
| Gain on sales of assets | $ | — | $ | — | $ | — | $ | 6,385 | $ | (6,385 | ) | $ | — | ||||||||||
| Operating income | $ | 51,853 | $ | 12,765 | $ | 64,618 | $ | 56,588 | $ | (5,087 | ) | $ | 51,501 | ||||||||||
| Debt retirement costs | $ | — | $ | — | $ | — | $ | 1,896 | $ | (1,896 | ) | $ | — | ||||||||||
| Loss on extinguishment of debt | $ | 2,442 | $ | (2,442 | ) | $ | — | $ | — | $ | — | $ | — | ||||||||||
| Income before income taxes | $ | 39,639 | $ | 15,207 | $ | 54,846 | $ | 28,294 | $ | (3,191 | ) | $ | 25,103 | ||||||||||
| Income tax (benefit) provision | $ | (83,746 | ) | $ | 99,805 | (c) | $ | 16,059 | $ | 1,532 | $ | — | $ | 1,532 | |||||||||
| Net income | $ | 123,385 | $ | (84,598 | ) | $ | 38,787 | $ | 26,762 | $ | (3,191 | ) | $ | 23,571 | |||||||||
| Net income per common share - diluted | $ | 3.17 | $ | 1.00 | $ | 0.82 | $ | 0.72 | |||||||||||||||
(a) One-time contract and termination costs.
(b) Includes campus consolidation costs (including depreciation expense) of $6.5 million, non-recurring refinancing related fees of $2.6 million, one-time contract and termination costs of $1.0 million, loss on impairment of land of $0.9 million and offering and other costs of $0.6 million.
(c) Includes the income tax effect of non-GAAP adjustments and the income tax benefit due to the release of our valuation allowance of $141.1 million against our deferred tax assets offset by a provision of $45.1 million for the remeasurement of our deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.
(d) Offering and other costs.
(e) Campus consolidation costs (including depreciation expense).
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||||||||||
|
(in thousands – unaudited) |
||||||||||||||||
|
Three Months Ended December 31, |
Year Ended |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Net income | $ | 97,126 | $ | 4,869 | $ | 123,385 | $ | 26,762 | ||||||||
| Interest expense, net | 4,257 | 5,816 | 18,391 | 26,598 | ||||||||||||
| Income tax (benefit) provision(a) | (92,759 | ) | 452 | (92,113 | ) | 477 | ||||||||||
| Depreciation | 2,419 | 3,529 | 12,485 | 9,915 | ||||||||||||
| Amortization of intangible assets | 1,794 | 2,070 | 6,747 | 8,348 | ||||||||||||
| EBITDA | 12,837 | 16,736 | 68,895 | 72,100 | ||||||||||||
| Stock and incentive plan compensation | 2,034 | 791 | 6,769 | 3,527 | ||||||||||||
| Asset write-off (b) | 1,246 | 818 | 3,430 | 1,906 | ||||||||||||
| Severance and recruiting costs (c) | 682 | 204 | 1,715 | 2,090 | ||||||||||||
| Offering and other costs (d) | (26 | ) | 117 | 576 | 126 | |||||||||||
| Campus consolidation costs | 51 | — | 1,152 | — | ||||||||||||
| Debt refinancing costs | 836 | — | 2,557 | — | ||||||||||||
| Extinguishment of debt and debt retirement costs | 281 | 481 | 2,442 | 1,896 | ||||||||||||
| Loss (gain) on sales of assets | — | 120 | — | (6,385 | ) | |||||||||||
| New manufacturer costs (e) | 688 | 578 | 4,304 | 3,029 | ||||||||||||
| One-time contract and termination costs | 2,210 | — | 2,210 | — | ||||||||||||
| Adjusted EBITDA | $ | 20,839 | $ | 19,845 | $ | 94,050 | $ | 78,289 | ||||||||
| Adjusted EBITDA, as a percentage of revenues | 25.7 | % | 26.7 | % | 28.4 | % | 25.9 | % | ||||||||
(a) Represents income tax (benefit) provision, less tax indemnification income associated with BMS. During the three and twelve months ended December 31, 2017, this amount includes the release of our valuation allowance against our deferred tax assets and changes enacted under the Tax Cuts and Jobs Act of 2017.
(b) Represents non-cash losses incurred associated with the write-down of land, inventory and other write-offs of long-lived assets. During the three and twelve months ended December 31, 2017, the amount includes an impairment of land of $0.9 million.
(c) The amounts consist of severance and recruitment costs related to employees, executives and directors.
(d) Represents offering costs incurred on behalf of certain shareholders pursuant to a registration rights agreement and other non-recurring costs.
(e) Represents internal and external costs associated with establishing new manufacturing sources for our commercial and clinical candidate products.
|
Lantheus Holdings, Inc. |
||||||||||||||||
|
Reconciliation of Free Cash Flow |
||||||||||||||||
|
(in thousands – unaudited) |
||||||||||||||||
|
Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Net cash provided by operating activities | $ | 13,086 | $ | 12,781 | $ | 54,777 | $ | 49,642 | ||||||||
| Capital expenditures | (5,954 | ) | (2,422 | ) | (17,543 | ) | (7,398 | ) | ||||||||
| Free cash flow | $ | 7,132 | $ | 10,359 | $ | 37,234 | $ | 42,244 | ||||||||
|
Lantheus Holdings, Inc. |
||||||||
|
Condensed Consolidated Balance Sheets |
||||||||
|
(in thousands – unaudited) |
||||||||
|
December 31, 2017 |
December 31, 2016 |
|||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 76,290 | $ | 51,178 | ||||
| Accounts receivable, net | 40,259 | 36,818 | ||||||
| Inventory | 26,080 | 17,640 | ||||||
| Other current assets | 5,221 | 5,183 | ||||||
| Total current assets | 147,850 | 110,819 | ||||||
| Property, plant & equipment, net | 92,999 | 94,187 | ||||||
| Intangibles, net | 11,798 | 15,118 | ||||||
| Goodwill | 15,714 | 15,714 | ||||||
| Deferred tax assets, net | 87,010 | 65 | ||||||
| Other long-term assets | 28,487 | 19,995 | ||||||
| Total assets | $ | 383,858 | $ | 255,898 | ||||
| Liabilities and stockholders’ equity (deficit) | ||||||||
| Current liabilities | ||||||||
| Current portion of long-term debt | $ | 2,750 | $ | 3,650 | ||||
| Revolving line of credit | — | — | ||||||
| Accounts payable | 17,464 | 18,940 | ||||||
| Accrued expenses and other liabilities | 26,536 | 21,249 | ||||||
| Total current liabilities | 46,750 | 43,839 | ||||||
| Asset retirement obligations | 10,412 | 9,370 | ||||||
| Long-term debt, net | 265,393 | 274,460 | ||||||
| Other long-term liabilities | 38,012 | 34,745 | ||||||
| Total liabilities | 360,567 | 362,414 | ||||||
| Total stockholders’ equity (deficit) | 23,291 | (106,516 | ) | |||||
| Total liabilities and stockholders’ equity (deficit) | $ | 383,858 | $ | 255,898 | ||||
